Vanguard reports 4.53% stake in Arrowhead
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of Arrowhead Pharmaceuticals Inc. common stock. The group holds 6,384,903 shares, representing 4.53% of the outstanding class of Arrowhead’s common stock.
Within this position, Vanguard Portfolio Management has sole voting power over 33,548 shares and sole dispositive power over 6,384,903 shares, with no shared voting or dispositive power reported. The stake is held across Vanguard investment companies and other managed accounts for which Vanguard entities exercise voting and/or dispositive authority. No other individual investor’s interest in the reported securities exceeds 5% of the class.
Key Figures
Key Terms
beneficially owned financial
dispositive power financial
Schedule 13G regulatory
Investment Company Act of 1940 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Arrowhead Pharmaceuticals (ARWR) does Vanguard Portfolio Management report owning?
Does any single Vanguard client own more than 5% of Arrowhead Pharmaceuticals (ARWR)?
Which Vanguard entities are included in the Arrowhead Pharmaceuticals (ARWR) ownership report?
AI-generated analysis. How Rhea-AI works. Not financial advice.